XNYS
ITGR
Market cap4.30bUSD
Oct 08, Last price
126.65USD
1D
0.05%
1Q
35.19%
Jan 2017
330.05%
IPO
521.14%
Name
Integer Holdings Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.
Key people
Pamela Bailey
Independent Chairman of the Board · since 2022
Payman Khales
President, Chief Executive Officer · since 2025
Diron Smith
Chief Financial Officer, Executive Vice President · since 2023
Jim Stephens
President - Cardiac Rhythm Management & Neuromodulation · since 2023
Kirk Thor
Executive Vice President, Chief Human Resources Officer · since 2018
Margaret Carthy
Executive Vice President - Quality and Regulatory Affairs · since 2024
John Harris
Executive Vice President - Global Operations and Manufacturing Strategy · since 2024
Andrew Senn
Senior Vice President - Strategy, Business Development and Investor Relations · since 2023
Tommy Thomas
Vice President & Corporate Controller · since 2018
Sheila Antrum
Independent Director · since 2021
Cheryl Capps
Independent Director · since 2021
Independent Director · since 2025
James Hinrichs
Independent Director · since 2018
Independent Director · since 2015
Alvin Jeffers
Independent Director · since 2021
Martin Maxwell
Independent Director · since 2015
Independent Director · since 2015
Donald Spence
Independent Director · since 2016
IPO date
Sep 29, 2000
Employees
10,000
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
5830 Granite Parkway
Suite 1150
Plano, TX 75024
US
Suite 1150
Plano, TX 75024
US
Previous name
Greatbatch, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑12 | 2017‑12 | 2017‑12 | 2016‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||